Access to COVID-19 Diagnostics
Testing the right people, at the right moment and with the right tool is essential for the Covid-19 pandemic management. Both the Swiss international cooperation and the Swiss pharmaceutical sector have a long-standing experience and interest in supporting R&D, access and manufacturing of diagnostics.. The Foundation for Innovative New Diagnostics (FIND) is leading the global effort (ACT-A Dx Partnership) in the development of affordable COVID-19 diagnostics and local manufacturing capacity for and in LMICs.
Country/region | Topic | Period | Budget |
---|---|---|---|
Global |
Health Employment & economic development
Infectious desease
Health systems strengthening Tradepolicy & market system |
01.09.2020
- 31.12.2023 |
CHF 26’000’000
|
- Other international or foreign NGO North
- Foundation for Innovative New Diagnostics (FIND)
-
Sector according to the OECD Developement Assistance Commitiee categorisation HEALTH
HEALTH
TRADE POLICY AND REGULATIONS
Sub-Sector according to the OECD Developement Assistance Commitiee categorisation Infectious disease control
Health policy and administrative management
Trade policy and administrative management
Aid Type Project and programme contribution
Project number 7F10613
Background |
|
|
Objectives | Accelerate universal and equitable access to safe, quality and effective COVID-19 diagnostics | |
Target groups |
- Researchers and clinicians in LMICs. - The global research and development community for COVID-19. - Manufacturers, regulators and procurement agencies (UNICEF, Global - Patients and population at high risk for COVID-19. |
|
Medium-term outcomes |
1. Local manufacturing capacity enhanced to meet regional demand 2. Countries are able to utilize digital solutions as part of their COVID response |
|
Results |
Expected results: - Research and Development: Accelerate development and availability of high performing, affordable rapid diagnostic tools, and create - Market readiness: Implement market shaping interventions to - Supply: Identification of supply availability, demand aggregation and ensure efficient logistics and delivery. - Country capacity building: Strengthen health systems and build Results from previous phases: Not applicable. This is a new proposal. |
|
Directorate/federal office responsible |
SDC |
|
Credit area |
Development cooperation |
|
Project partners |
Contract partner International or foreign NGO Other partners Governments, NGOs, private sector |
|
Coordination with other projects and actors | The ACT-A initiative on therapeutics (Wellcome Trust) and vaccine (Gavi), the WHO Blue Print Project. The Global Fund, WHO | |
Budget | Current phase Swiss budget CHF 26’000’000 Swiss disbursement to date CHF 25’999’550 | |
Project phases |
Phase 1 01.09.2020 - 31.12.2023 (Completed) |